Moreno, Lucas, Caron, Hubert, Geoerger, Birgit, Eggert, Angelika, Schleiermacher, Gudrun, Brock, Penelope, Valteau-Couanet, Dominique, Chesler, Louis, Schulte, Johannes H, De Preter, Katleen, and others. (2017) Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project. Expert Opinion on Drug Discovery, 12 (8). pp. 801-811. ISSN 1746-0441. E-ISSN 1746-045X. (doi:10.1080/17460441.2017.1340269) (KAR id:63861)
|
PDF
Author's Accepted Manuscript
Language: English |
|
|
Download this file (PDF/439kB) |
Preview |
| Request a format suitable for use with assistive technology e.g. a screenreader | |
|
PDF (Abbreviations)
Supplemental Material
Language: English |
|
|
Download this file (PDF/185kB) |
Preview |
| Request a format suitable for use with assistive technology e.g. a screenreader | |
|
PDF (Table 1)
Supplemental Material
Language: English |
|
|
Download this file (PDF/375kB) |
Preview |
| Request a format suitable for use with assistive technology e.g. a screenreader | |
|
PDF (Table 2)
Supplemental Material
Language: English |
|
|
Download this file (PDF/243kB) |
Preview |
| Request a format suitable for use with assistive technology e.g. a screenreader | |
|
PDF (Table 3)
Supplemental Material
Language: English |
|
|
Download this file (PDF/285kB) |
Preview |
| Request a format suitable for use with assistive technology e.g. a screenreader | |
| Official URL: http://dx.doi.org/10.1080/17460441.2017.1340269 |
|
Abstract
Introduction: Neuroblastoma, the commonest paediatric extra-cranial tumour, remains a leading cause of death from cancer in children. There is an urgent need to develop new drugs to improve cure rates and reduce long-term toxicity and to incorporate molecularly targeted therapies into treatment. Many potential drugs are becoming available, but have to be prioritised for clinical trials due to the relatively small numbers of patients.
Areas covered: The current drug development model has been slow, associated with significant attrition, and few new drugs have been developed for neuroblastoma. The Neuroblastoma New Drug Development Strategy (NDDS) has: 1) established a group with expertise in drug development; 2) prioritised targets and drugs according to tumour biology (target expression, dependency, pre-clinical data; potential combinations; biomarkers), identifying as priority targets ALK, MEK, CDK4/6, MDM2, MYCN (druggable by BET bromodomain, aurora kinase, mTORC1/2) BIRC5 and checkpoint kinase 1; 3) promoted clinical trials with target-prioritised drugs. Drugs showing activity can be rapidly transitioned via parallel randomised trials into front-line studies.
Expert opinion: The Neuroblastoma NDDS is based on the premise that optimal drug development is reliant on knowledge of tumour biology and prioritisation. This approach will accelerate neuroblastoma drug development and other poor prognosis childhood malignancies.
| Item Type: | Article |
|---|---|
| DOI/Identification number: | 10.1080/17460441.2017.1340269 |
| Uncontrolled keywords: | Neuroblastoma, drug development, phase I, preclinical testing, clinical trials |
| Subjects: | Q Science |
| Divisions: | Divisions > Division of Natural Sciences > Biosciences |
| Depositing User: | Michelle Garrett |
| Date Deposited: | 06 Oct 2017 08:31 UTC |
| Last Modified: | 05 Nov 2024 10:59 UTC |
| Resource URI: | https://kar.kent.ac.uk/id/eprint/63861 (The current URI for this page, for reference purposes) |
University of Kent Author Information
Garrett, Michelle D..
| Creator's ORCID: |
 https://orcid.org/0000-0002-3939-1673
|
|---|---|
| CReDIT Contributor Roles: |
- Link to SensusAccess
- Export to:
- RefWorks
- EPrints3 XML
- BibTeX
- CSV
- Depositors only (login required):
Altmetric
Altmetric
